Page 16 - 202002

[2] 阮江雄，谢丽萍.人胰高血糖素样 [10] Rosenstock J, Allison D,

肽-1受体激动药索马鲁肽的研究进展 [J]. Birkenfeld AL, et al. Effect of Additional
世界临床药物，2018.39(12):856-863. Oral Semaglutide vs Sitagliptin on
Glycated Hemoglobin in Adults With Type
[3] 李艳梅，唐伟偌.索马鲁肤口服剂:
开启GLP -1受体激动药的新时代 [J]. 药品 2 Diabetes Uncontrolled With Metformin

评价，2019.16（24）：1-5. Alone or With Sulfonylurea: The
PIONEER 3 Randomized Clinical Trial [J].
[4] Vsramini P, Toth I. Recent JAMA. 2019. 321(15): 1466-1480.

advances in oral delivery of peptide
hormones [J]. Expert Opin Drug Deliv, [11] Pratley R, Amod A, Hoff ST, et
2016, 13(4):507-522. al. Oral semaglutide versus
subcutaneous liraglutide and placebo in
[5] 葛阳.口服GLP-1受体激动药的研究 type 2 diabetes(PIONEER 4): a

进展[J].药物生物技术，2018,25(6):533- randomised,double-bfind, phase 3a trial
536. [J]. Lancet, 2019, 394(10192): 39-50.

[6] John D, Lauren G, Nicole Carter, [12] Mosenzon O, Blicher TM,
et al. Oral Semaglutide: A Review of the Rosenlund S, et al. Efficacy and safety of
First Oral Glucagon-Like Peptide-1 oral semaglutide in patients with type 2
Receptor Agonist [J] Diabetes Technology diabetes and moderate renal

and Therapeutics,2019,22（1）:1-27. impairment(PIONEER 5): a placebo-

[7] Maher S, Mrsny RJ, Brayden DJ. controlled, randomised, phase 3a trial [J].
Intestinal permeation enhancers for oral Lancet Diabetes Endocrinol, 2019, 7(7):

peptide delivery [J]. Adv Drug Deliv Rev, 515-527.
2016,106(PtB):277-319. [13] Husain M, Birkenfeld AL,

[8] Aroda VR, Rosenstock J, Donsmark M, et al. Oral Semaglutide and

Terauchi Y, et al. PIONEER Cardiovascular Outcomes in Patients with
1:Randomized Clinical Trial of the Type 2 Diabetes [J]. N Engl J Med,2019,

Efficacy and Safety of Oral Semaglutide 381(9): 841-851.
Monotherapy in Comparison With [14] Pieber TR, Bode B, Mertens A,
Placebo in Patients With Type 2 Diabetes et al. Efficacy and safety of oral
[J]. Diabetes Care, 2019, 42(9): 1724- semaglutide with flexible dose adjustment

1732. versus sitagliptin in type 2

[9] Rodbard HW, Rosenstock J, diabetes(PIONEER 7): a multicentre,
Canani LH, et al. Oral Semaglutide open-label, randomised, phase 3a trial

Versus Empagliflozin in Patients With [J]. Lancet Diabetes Endocrinol, 2019,
Type 2 Diabetes Uncontrolled on 7(7): 528-539.

Metformin:The PIONEER 2 Trial [J].
Diabetes Care, 2019, 42(12): 2272-2281.

c̾̿ḤḤc